Alnylam Pharmaceuticals, Inc.(ALNY)Stock Performance & ReturnsNASDAQ
Returns, drawdowns and benchmark comparison
Peer Comparison
Relative scale, growth, and profitability vs sector peers
| Ticker | Market Cap | P/E Ratio | Revenue Growth | Net Margin | EPS | ROE | Debt/Equity | Dividend Yield | 52W High | 52W Low |
|---|---|---|---|---|---|---|---|---|---|---|
ALNY | 30.03 B | 41.63x | 66.90% | 16.13% | $5.39 | 96.56% | 2.21x | 0.00% | $495.55 | $197.81 |
GILD | 182.09 B | - | 10.20% | -10.64% | -$2.63 | -20.68% | 2.23x | 2.18% | $154.51 | $105.84 |
VRTX | 128.16 B | 29.67x | 12.50% | 35.00% | $17.04 | 23.54% | 9.77x | 0.00% | $560.25 | $400.74 |
REGN | 75.06 B | 18.36x | 16.70% | 27.87% | $40.41 | 14.04% | 8.54x | 0.50% | $859.34 | $538.24 |
950220.KQ | 62.53 B | - | 4559.30% | 0.00% | - | -61.03% | 0.20x | - | $4450.00 | $1115.00 |
Peer Valuation & Performance Analysis
Peer group analysis for Alnylam Pharmaceuticals, Inc. (ALNY) compared to its primary competitors (including GILD, VRTX, REGN) reveals distinct metrics. ALNY trades at a valuation premium compared to its competitors, with a P/E ratio of 41.6x versus the peer average of -2.6x (representing a -1702% premium). This indicates that the market expects superior growth or commands a quality premium for ALNY. In terms of growth, ALNY's revenue growth of 66.9% lags behind the peer average of 1149.7%, indicating potential market share losses or slower industry adoption. Additionally, it boasts superior profitability with a net margin of 16.1% compared to the peer average of 13.1%, demonstrating strong cost controls and pricing power.
Peer Performance Rankings
Ranking comparison across key performance metrics
P/E Ratio (Lower is Better)
Revenue Growth
Net Profit Margin
Financial Rankings Summary
• ALNY ranks #3 in P/E ratio, #2 in revenue growth, and #3 in profit margins
• Average ranking: #3 - 📊 Solid financials relative to peer group
• Rankings based on actual financial data from company reports
Historical Trading Data
Price and volume data with customizable timeframes
Showing 15 of 15 trading sessions from the last 15 days
| Date | Open | High | Low | Close | Volume | Daily Change |
|---|---|---|---|---|---|---|
| 2026-10-07 | $224.39 | $230.42 | $222.46 | $224.41 | 1,064,100 | +0.21% |
| 2026-10-06 | $221.02 | $229.18 | $217.18 | $223.94 | 1,356,300 | +1.84% |
| 2026-10-05 | $218.36 | $222.08 | $215.46 | $219.89 | 1,281,100 | +0.08% |
| 2026-10-02 | $231.31 | $231.36 | $219.40 | $219.72 | 1,661,700 | -4.96% |
| 2026-10-01 | $248.21 | $251.71 | $230.06 | $231.18 | 2,017,300 | -6.31% |
| 2026-09-30 | $253.68 | $254.44 | $246.66 | $246.74 | 1,044,400 | -2.89% |
| 2026-09-29 | $254.86 | $257.27 | $251.02 | $254.07 | 786,900 | -0.51% |
| 2026-09-28 | $256.28 | $256.60 | $248.12 | $255.36 | 1,147,900 | -0.23% |
| 2026-09-25 | $248.39 | $256.66 | $247.51 | $255.96 | 1,084,500 | +2.55% |
| 2026-09-24 | $246.51 | $251.81 | $245.52 | $249.59 | 933,700 | +1.25% |
| 2026-09-23 | $249.99 | $253.81 | $245.34 | $246.51 | 1,481,700 | -2.04% |
| 2026-09-22 | $246.86 | $255.51 | $244.13 | $251.65 | 1,131,800 | +3.00% |
| 2026-09-21 | $240.37 | $247.10 | $237.97 | $244.32 | 1,152,700 | +1.99% |
| 2026-09-18 | $246.41 | $246.49 | $238.51 | $239.56 | 2,755,000 | -2.42% |
| 2026-09-17 | $242.60 | $245.63 | $239.50 | $245.51 | 1,006,500 | +2.57% |
Explore More Analysis for ALNY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.